Form 4: Stoke Therapeutics CMO Sells Shares in Routine Transactions

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, reported multiple sales of common stock, including tax-related withholdings and transactions under a 10b5-1 plan.

Summary

• Chief Medical Officer Barry Ticho reported multiple transactions involving Stoke Therapeutics, Inc. common stock.
• On March 17, 2026, Ticho sold a total of 6,164 shares (3,577 and 2,587) at weighted average prices of $32.7394 and $33.3754, respectively, to cover tax withholding liabilities from restricted stock unit vesting.
• On March 18, 2026, Ticho sold an additional 6,686 shares (6,100, 483, and 103) at weighted average prices of $31.2838, $31.7888, and $32.85, also for tax withholding.
• On March 19, 2026, Ticho exercised options to acquire 1,365 shares at $2.19 per share and subsequently sold 1,461 shares at $29.99 per share, both executed under a Rule 10b5-1 trading plan adopted on November 19, 2025.
• Following these transactions, Ticho beneficially owns 40,702 shares of common stock and 83,035 stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are largely routine, involving tax-related sales and a pre-planned 10b5-1 sale, which do not typically indicate a change in management's confidence or company prospects.

Positives

• Transactions related to tax withholding are routine for executive compensation and do not necessarily indicate a change in sentiment.
• The exercise and sale on March 19, 2026, were executed under a pre-arranged Rule 10b5-1 trading plan, indicating planned rather than reactive selling.
• A significant number of stock options (83,035) remain beneficially owned by the Chief Medical Officer.

Negatives

• The sales represent a reduction in direct common stock ownership by the Chief Medical Officer.
• The sales occurred at various prices, with some below the higher end of the reported ranges.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax withholding or pre-arranged 10b5-1 plans, are common occurrences for executives in the biotechnology sector. These routine filings typically do not signal a change in company fundamentals or strategic direction, unlike large, unscheduled open-market sales.

Key Dates

Keywords

Stoke Therapeutics, STOK, Insider Trading, Form 4, Barry Ticho, Chief Medical Officer, Stock Sales, Option Exercise, 10b5-1 Plan, Restricted Stock Units